1 December 2016 - Drugmakers have ‘false sense of relief’ over Trump win.

Donald Trump’s victory in the presidential race, often cited as a boon to free-market health care, doesn’t mean drugmakers are free of scrutiny over prices, an industry leader said.

U.S. pharmaceutical shares rose after the defeat of Democratic candidate Hillary Clinton, who had vowed to go after companies’ “gouging.” Yet if more pricing scandals emerge like the one that beset Mylan's EpiPen, President-elect Trump could be more “vicious” than Clinton, Allergan Chief Executive Officer Brent Saunders said Thursday.

Read Bloomberg article